Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX140-B in diabetic nephropathy
ISRCTN77691094Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Nov 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ilacirnon in diabetic glomerulosclerosis (3 arms), sponsored by ChemoCentryx. Primary endpoint: Safety and tolerability of CCX140-B. Started Nov 2011; status: completed.
02
Drugs
ilacirnon
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ISRCTN77691094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77691094.